A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ) ) Versus Triple Therapy Regimen (Reiferon Retard + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard + Ribavirin) in the Treatment of Naive Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)

Trial Profile

A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ) ) Versus Triple Therapy Regimen (Reiferon Retard + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard + Ribavirin) in the Treatment of Naive Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Alfacalcidol (Primary) ; Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top